Danone and Nestle have remained silent over reports that each company has submitted competing preliminary bids for Pfizer’s baby food business.
According to a Bloomberg report, which cited two unnamed sources, Danone and Nestle have both offered around US$10bn for the business and are now looking at how to overcome antitrust hurdles.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bloomberg suggested that Nestle is considering buying Pfizer wholesale and auctioning off businesses that would raise regulatory concerns, while Danone is reportedly weighing a joint bid with Mead Johnson Nutrition.
Danone and Nestle declined to comment on the reports.
Meanwhile, a spokesperson for drug-maker Pfizer told just-food that the group had yet to make a decision over the future of the unit, which generated revenues of $2.14bn last year.
“We are still exploring options,” the spokesperson said. “These could include – but are not limited to – a sale or spin-off of the business.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
